Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis

PURPOSE: Treatment of refractory Hodgkin disease deserves specific considerations. Recently, alemtuzumab-BEAM has been introduced in allogeneic hematopoietic stem cell transplantation (HSCT) in these patients. METHODS: We retrospectively analyzed the outcome of 20 patients with relapsed/refractory H...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabitsch, W., Bojic, M., Wohlfarth, P., Leiner, M., Schörgenhofer, C., Kalhs, P., Schulenburg, A., Sillaber, C., Mitterbauer, M., Sperr, W. R., Jäger, U., Skrabs, K., Greinix, H., Hermann, A., Lamm, W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865538/
https://www.ncbi.nlm.nih.gov/pubmed/26920356
http://dx.doi.org/10.1007/s00432-016-2134-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865538/
https://www.ncbi.nlm.nih.gov/pubmed/26920356
http://dx.doi.org/10.1007/s00432-016-2134-3

Ejemplares similares